Looking for an early success in PhII Alzheimer’s study, Biogen and Eisai just racked up the latest setback
Chalk up another big setback for the amyloid beta theory and another failed attempt at blazing a clinical path to success.
Investigators for Biogen $BIIB and Eisai say that their anti-amyloid beta antibody BAN2401 flunked the 12-month primary endpoint in their Phase II study. They had hoped that using Bayesian analysis methods would set them up for an early win, based on a new goal for success using a composite disease score with the patients enrolled. Now they will go on to the full 18 month mark and then run a check of biomarkers for the disease — which has proven to be a remarkably unreliable assessment for clinical efficacy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.